This clinical overview details the latest evidence-based strategies for diagnosing and treating symptoms of benign prostatic hyperplasia in men.

The FDA has approved tadalafil (Cialis) for the once daily use as a treatment for benign prostatic hyperplasia (BPH). The agency also approved the medication for once daily use as a treatment for men ...

Treatment with vibegron reduced the average number of micturition episodes per day and the average number of daily urgency episodes compared with placebo. The Food and Drug Administration (FDA) has ...

Retreatment after benign prostatic hyperplasia (BPH) procedures appear lowest for men undergoing simple prostatectomy, HoLEP, ...

Teleflex Incorporated announced the presentation of multiple clinical studies at the 2025 American Urological Association Annual Meeting in Las Vegas, highlighting advancements in treatments for ...

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Zenflow, Inc. announced today the U.S. Food and Drug Administration (FDA) approval of the Zenflow Spring(R) Implant and Delivery System ...

Benign prostatic hyperplasia (BPH) is one of the most common urologic conditions affecting men as they age, with nearly 50% of men over 50 experiencing symptoms. Despite its prevalence, treatment ...

Our extensive research on the Benign Prostatic Hyperplasia Treatment (2024-2032) offers valuable insights for businesses. This comprehensive report delves into emerging trends, in ...

A regulatory decision is expected in the third quarter of 2024. The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for vibegron for the treatment of men ...

Add Yahoo as a preferred source to see more of our stories on Google. Men aged 50 and above are most commonly affected. (Getty Images) (Rafael Ben-Ari via Getty Images) This common condition affects ...